Evogene (EVGN) Operating Expenses (2012 - 2026)

Evogene has disclosed Operating Expenses across 15 years of filings, most recently posting $2.7 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 10.17% year-over-year to $2.7 million; the TTM figure through Jun 2026 stood at $12.2 million (down 31.62% YoY), while the FY2025 annual figure was $11.4 million, down 48.02% from the prior year.
• Operating Expenses came in at $2.7 million for Q2 2026 at Evogene, down from $3.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $8.1 million in Q1 2022 to a low of $2.7 million in Q2 2026.
• Average Operating Expenses over 5 years is $5.6 million, with a median of $5.8 million recorded in 2024.
• Year-over-year, Operating Expenses surged 91.47% in 2023 and sank 56.5% in 2025.
• Over 5 years, Operating Expenses stood at $4.1 million in 2022, then soared by 91.47% to $7.8 million in 2023, then slumped by 44.53% to $4.3 million in 2024, then slipped by 25.14% to $3.2 million in 2025, then fell by 16.59% to $2.7 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $2.7 million in Q2 2026, $3.4 million in Q1 2026, and $3.2 million in Q4 2025.